CompletedPhase 2NCT00520767
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Studying Primary systemic amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Principal Investigator
- Jeffrey A. Zonder, MD, M.DBarbara Ann Karmanos Cancer Institute
- Intervention
- bortezomib(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2007 – 2019
Study locations (7)
- Rocky Mountain Cancer Centers/Rocky Mountain Blood & Marrow Transplant Program, Denver, Colorado, United States
- Boston University Cancer Research Center, Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
- Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
- Duke Comprehensive Cancer Center, Durham, North Carolina, United States
- UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00520767 on ClinicalTrials.govOther trials for Primary systemic amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06627309Rapid dFLC Response Predict CHR in AL AmyloidosisPeking University People's Hospital
- RECRUITINGNANCT06803082The Impact of Systemic Light Chain Amyloidosis on EyesZhongshan Ophthalmic Center, Sun Yat-sen University
- RECRUITINGNANCT02641145Molecular Imaging of Primary Amyloid CardiomyopathyBrigham and Women's Hospital